30th Mar 2009 17:30
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DTR 3.1.4R
We hereby inform you that on 27 March 2009 the following Directors of AstraZeneca PLC were granted options under the AstraZeneca Share Option Plan over the Company's USD0.25 Ordinary Shares.
|
Name of Director |
Number of shares over which option is granted |
Exercise price per share |
Period when exercisable |
Total number of shares under option |
|
D R Brennan |
160,016 |
2280p |
27.3.12-26.3.19 |
See below |
|
S Lowth |
65,131 |
2280p |
27.3.12-26.3.19 |
153,934 |
The options will become exercisable on 27 March 2012 subject to certain performance conditions. The conditions, which will not be subject to any retesting, are that the earnings per share of the Company must increase by the increase in the UK Retail Prices Index plus 5% per annum on average over three years, and that no significant unforeseen event has taken place which, in the reasonable opinion of the Remuneration Committee, has resulted in major reputational damage to AstraZeneca, and the circumstances of which are exceptional enough to justify the option not vesting and becoming exercisable. Failure to satisfy either or both of these conditions will result in the lapse of the option in its entirety.
David R Brennan, a Director of the Company, has previously received grants of options over the Company's American Depositary Shares (ADSs). One ADS equals one Ordinary Share. Following the grant of options referred to above, David Brennan has options over 592,975 Ordinary Shares and 355,246 ADSs.
A C N Kemp
Company Secretary
30 March 2009
Related Shares:
Astrazeneca